Anyone wishing to take issue with the draft recommendation to not make daclizumab1 (Zinbryta) be made available as a treatment on the NHS in England and Wales has just 15 days to do so. Comments must be received by Friday October 21.
So, if you want a change of heart, don’t delay. The time to stand up for MS patients is now!
The UK’s National Institute for Health and Care Excellence (NICE) is responsible for evaluating new drugs and treatments, along with their costs. It then makes recommendations as to whether or not they should be available through the country’s National Health Service (NHS) in England and Wales. Other parts of the UK have their own guidance bodies.
In a document published on the NICE website, the appraisal committee’s preliminary recommendation states: “Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults.”
The committee was critical of the analysis submitted by the manufacturer of the cost effectiveness of daclizumab, compared with other disease modifying treatments.
The NICE appraisal committee is scheduled to have another meeting on November 2. It is expected to review the comments received together with further evidence from the manufacturer.
NICE is expected to publish its final guidance next year.
1 Daclizumab is an experimental drug treatment being developed for relapsing MS. It is taken as an injection under the skin, once a month. In clinical trials, daclizumab reduced relapse rates by approximately 50% compared to placebo and by 45% compared to beta interferon. The drug was licensed in Europe in July 2016.
Serious infections, serious skin reactions and impaired liver function occurred more frequently in people treated with daclizumab than in other treatment groups.